Skip To Main Content
Soyi Liu Leage on Muck Rack

Soyi Liu Leage

As seen in: Annals of the Rheumatic Diseases
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Soyi Liu

Contact Soyi Liu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

|
By Denis Poddubnyy, Proton Rahman, Rebecca Bolce, Soyi Liu Leage
| Annals of the Rheumatic Diseases Verified
Antirheumatic Agents Spondylitis, Ankylosing Biological Therapy Immune System Diseases WHAT IS ALREADY KNOWN ON THIS TOPIC Previous randomised withdrawal studies of tumour necrosis factor inhibitors suggest continuous treatment is important in maintaining clinical response in patients with axial spondyloarthritis (axSpA) and that discontinuation may lead to loss of efficacy when restarted.
Open in Who Shared Issue with article?

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study

|
By Denis Poddubnyy, Proton Rahman, Rebecca Bolce, Soyi Liu Leage
| Annals of the Rheumatic Diseases Verified
Discussion COAST-Y is the first study to compare the maintenance of disease control in patients with axSpA who continued versus those who withdrew an IL-17A antagonist (IXE) after having achieved remission. This analysis demonstrates that the majority of patients who were withdrawn from IXE to placebo and experienced a flare recaptured either ASDAS LDA or ID within 16 weeks of OL IXE retreatment.
Open in Who Shared Issue with article?
See all 2 articles